Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences. A plethora of symptoms and their severity differentiate on an individual level, giving the syndrome numerous phenotypes. Due to menstru...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinkovic-Radosevic, Jelena, Cigrovski Berkovic, Maja, Kruezi, Egon, Bilic-Curcic, Ines, Mrzljak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311482/
https://www.ncbi.nlm.nih.gov/pubmed/34326946
http://dx.doi.org/10.4239/wjd.v12.i7.932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311482/
https://www.ncbi.nlm.nih.gov/pubmed/34326946
http://dx.doi.org/10.4239/wjd.v12.i7.932

Ejemplares similares